In the phase I study of NCT02013219, erlotinib combined with atezolizumab in EGFR mutation-positive (19 deletions and 21 L858R) advanced NSCLC patients who did not use TKI achieved 75% ORR (Ma et al., 2016a). This evidence concerns the gene EGFR and non-small cell lung carcinoma.